Why MGM 15 & MGM 16 Derivatives aren’t the Same as Plain Leaf Kratom

MGM 15 and MGM 16

MGM-15 and MGM-16 are fully-synthetic compounds, and they are far more potent and pharmacologically distinct than 7-hydroxymitragynine (7-OH). While 7-OH occurs naturally in the kratom leaf in trace amounts and acts as a relatively short-lived partial agonist at the mu-opioid receptor, MGM-15 and MGM-16 are fully synthetic analogs engineered for stronger and longer receptor activation. Laboratory binding assays, such as the [³⁵S]GTPγS binding studies shown in the figure, demonstrate that both MGM compounds display significantly higher efficacy and affinity than 7-OH or even traditional opioid reference compounds. This means they engage the opioid system more intensely and for longer durations, placing them in an entirely different pharmacological category from natural kratom alkaloids. In short, 7-OH is a minor metabolite; MGM-15 and MGM-16 are potent designer opioids.

A new review in Drug Testing and Analysis highlights the rise of semi-synthetic compounds derived from kratom alkaloids (often called “MGM-15” series) and related potent analogs, including MGM-15 and MGM-16. These differ fundamentally from traditional, plain-leaf kratom. U.S. regulators now move to control 7-hydroxymitragynine (7-OH) due to opioid-like risk profiles, while not targeting the natural kratom leaf.

To further understand these compounds, it’s essential to recognize the historical context of kratom use. Traditionally, kratom has been utilized for its various therapeutic properties by indigenous communities in Southeast Asia. This long-standing tradition is based on the natural benefits of the plant, which include relief, increased energy, and enhanced mood. As the kratom market evolved, it began to attract a wider audience, leading to an influx of products that often prioritize potency over safety. This shift has raised concerns about the quality and integrity of the kratom being consumed.

The Industry’s Fork in the Road

The emergence of semi-synthetic derivatives, such as MGM-15, represents a significant departure from traditional practices. These new compounds are often marketed as alternatives to natural kratom, promising faster results and enhanced effects. However, the lack of regulation and standardization in the production of these products raises critical safety concerns. Consumers may unknowingly expose themselves to higher risks associated with synthetic substances that do not undergo the same rigorous testing as natural kratom.

Moreover, the potential for addiction and adverse side effects associated with these synthetic compounds cannot be overstated. Reports indicate that users may experience withdrawal symptoms far more severe than those typically associated with plain-leaf kratom. This is particularly alarming given the increasing popularity of products containing MGM 15 and similar derivatives, which can easily be obtained without proper oversight.

The kratom industry was built on tradition, truth, and transparency. Farmers in Indonesia have harvested this leaf for generations, and people like me have relied on it for balance, relief, and a better quality of life. But recently, science journals and regulators have started warning about something different: semi-synthetic kratom derivatives (nicknamed MGM compounds, including MGM-15) and synthetic 7-hydroxymitragynine (7-OH).

These aren’t plain leaf. They’re lab-engineered chemicals designed to mimic or amplify opioid activity. And they’re exactly why we need clear regulations that protect natural kratom but shut the door on risky synthetics.

Understanding the distinction between plain leaf and lab-engineered products is crucial for consumers. For instance, while plain-leaf kratom contains a balanced mix of alkaloids, lab tweaks might isolate one or two compounds, significantly altering the intended effects and safety profile. This could lead to unpredictable user experiences, where the same product affects different individuals in drastically different ways. In light of this, consumers are encouraged to educate themselves on the various forms of kratom available and their respective benefits and drawbacks.

If you want to see the science for yourself, here’s the Certificate of Analysis (COA) page where we share lab testing results for every batch we sell. Transparency is non-negotiable.

The marketing tactics employed by some companies also deserve scrutiny. Terms like ‘natural’ and ‘organic’ can be misleading when applied to semi-synthetic products. It’s essential for consumers to critically evaluate the claims made by manufacturers and seek third-party lab analyses to verify the authenticity of the product they are purchasing. The responsibility of ensuring product safety does not solely lie with regulators; consumers must also be proactive in their research and decision-making processes.

Plain Leaf vs. Lab Tweaks

• Plain Leaf: A natural spectrum of alkaloids, including mitragynine, that work together in a balanced way. It’s what farmers grow, and what consumers like you and me brew into tea. Want to understand it better? Start with our Beginner’s Plain-Leaf Kratom Guide.
• MGM Derivatives: Ultra-concentrated or fully synthetic compounds created in labs. Natural kratom has only trace amounts of 7-OH—fractions of a percent—but gas-station kratom is pushing 20–100 mg tablets. That’s not kratom; that’s chemistry pretending to be kratom.

Ultimately, the choices consumers make today will influence the future landscape of the kratom industry. Staying informed about the differences between natural and synthetic products is essential for making safe and responsible choices. Engaging in discussions and sharing knowledge with others can help foster a community committed to the preservation of kratom’s legacy while advocating for the safety and well-being of its users.

Regulators Are Paying Attention

On July 29, 2025, the FDA recommended scheduling 7-OH as a controlled substance, while making clear that natural kratom leaf wasn’t the target. The UN Office on Drugs and Crime also issued alerts on high-dose 7-OH appearing in vapes and gummies.

That distinction matters. Plain leaf deserves protection, not prohibition. That’s why we back legislation like the Kratom Consumer Protection Act (KCPA), which sets age limits, requires COAs, and bans synthetics—all while keeping natural kratom available for those who depend on it.

As we navigate these complex issues, it is crucial for consumers to remain vigilant and proactive. By demanding transparency, supporting responsible legislation, and prioritizing natural products like plain-leaf kratom, we can work together to ensure that the integrity of this remarkable plant is preserved for generations to come. The kratom community has the power to influence positive change, but it requires awareness and collective action to protect our rights and the legacy of kratom.

In conclusion, it is vital to understand that kratom has a rich history and a unique place in the world of natural remedies. By choosing to support traditional kratom products and advocating against synthetic derivatives like MGM-15, we can ensure that this incredible leaf continues to be a source of wellness, tradition, and community for years to come.

Why You Should Care?

Every week on Christopher’s Weekly Tea Talks, I sit down with other consumers and advocates to have real conversations about kratom—what’s safe, what’s hype, and how to make sure future generations have access to the leaf. The rise of synthetics is one of the biggest threats we’ve faced since the first federal ban attempts in 2016.

If we don’t separate plain-leaf tradition from lab-concocted shortcuts, regulators will do it for us and not in a way that helps consumers.

Bottom Line

Stick with tested, plain-leaf kratom. Avoid anything that brags about “high 7-OH content” or “MGM-style” compounds. Demand COAs. Support KCPA-style regulation. And never let synthetic shortcuts erase centuries of tradition.

Kratom is a leaf, not a lab experiment. God made it that way. Let’s keep it that way.